Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Launched by LEBANESE UNIVERSITY · Mar 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with solid tumors, such as colorectal, breast, lung, and ovarian cancers. The study is testing a combination of two targeted therapies: Palbociclib, which helps stop cancer cells from growing, and Bevacizumab, which prevents tumors from developing their own blood supply. The aim is to see if using these two drugs together can improve treatment outcomes and reduce side effects. Additionally, the trial will look at specific markers in the body, called Long Non-Coding RNAs (LncRNAs), to help personalize treatment for each patient based on their unique cancer characteristics.

To participate in this trial, individuals must be 18 years or older and be diagnosed with certain types of advanced cancer (stage III or IV). They should not have a history of certain other health conditions, including blood cancers or autoimmune diseases. If you join the trial, you will receive close monitoring and care throughout the study, and you may benefit from a treatment plan tailored to your specific cancer type. This innovative approach aims to provide better results for patients facing these challenging cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals of white ethnicity.
• • Age between \> 18
• • Both males and females.
• • Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer).
• • Cancer stage III/ IV with or without metastasis or lymph node dissemination at the time of enrollment.
• • Unrelated patients.
• Exclusion Criteria:
• • History of hematological cancer types or previous cancers, recurrent or relapse.
• • Diagnosis of inflammatory bowel diseases.
• • Pre-existing cardiovascular diseases or coronary artery diseases.
• • Confirmed treated or untreated autoimmune diseases.
• • Metabolic disorders, diabetes, or hypertension.
• • Neurological diseases.
• • Evidence of cardiac, renal, bone, or cerebral damage.
• • Presence of more than one type of malignancies.
• • Active infections or myositis.
• • Familial polyposis.
• • Alcohol or smoking habits.
• • Body mass index (BMI) \>30.
• • Significant weight loss within the last 2 years.
• • History of surgeries.
• • Pregnancy.
• • Related patients.